IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients-Reference-Cited by-同舟云学术

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

Published:2013-12-02 Issue:1 Volume:124 Page:99-110
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Sim Geok Choo,Martin-Orozco Natalia,Jin Lei,Yang Yan,Wu Sheng,Washington Edwina,Sanders Deborah,Lacey Carol,Wang Yijun,Vence Luis,Hwu Patrick,Radvanyi Laszlo

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference66 articles.

1. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

2. Next Generation of Immunotherapy for Melanoma

3. Interleukin-2

4. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology;Clinical Immunology;2024-09

2. Association of CTACK, IL-2, and IL-13 with increased risk of lung cancer: A Mendelian randomization study;Cytokine;2024-09

3. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

4. IL-2 based cancer immunotherapies: an evolving paradigm;Frontiers in Immunology;2024-07-24

5. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy;mAbs;2024-07-23